Helus Pharma (HELP) vs Neurogene (NGNE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Neurogene (NGNE) has outperformed Helus Pharma (HELP) over the past year, gaining 10.4% versus a gain of 9.3%. Over five years, NGNE leads with a -78.3% price change compared with -88.1% for HELP. Helus Pharma is the larger company by market cap ($487.7 million vs $458.5 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HELP | NGNE |
|---|---|---|
| Share price | $6.11 | $22.15 |
| Market cap | $487.68M | $458.53M |
| 1-day change | -9.88% | -3.40% |
| YTD return | -25.31% | +7.52% |
| 1-year return | +9.30% | +10.42% |
| 5-year return | -88.09% | -78.33% |
| EPS (TTM) | $-4.25 | $-5.03 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $0 |
| Revenue growth (YoY) | — | -100.00% |
| Net income (latest FY) | — | $-90.35M |
| 52-week high | $15.15 | $43.66 |
| 52-week low | $3.76 | $15.93 |
| Distance from 52-week high | -59.67% | -49.27% |
| Analyst consensus | none | strong_buy |
| Avg. price target upside | +564.81% | +250.47% |
| Average volume | 1.83M | 307.78K |
| Shares outstanding | 79.81M | 20.70M |
| Employees | 100 | 131 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Helus Pharma
HELP stock →Helus Pharma Inc. operates as a clinical stage pharmaceutical company that focuses on developing therapies to treat psychiatric and neurological conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
About Neurogene
NGNE stock →Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 131 employees
HELP vs NGNE FAQ
Which is bigger, Helus Pharma or Neurogene?
Helus Pharma (HELP) is larger, with a market capitalization of $487.68M compared with $458.53M for Neurogene (NGNE).
Which stock has performed better over the past year, HELP or NGNE?
NGNE returned +10.42% over the past 12 months, compared with +9.30% for HELP (price return, excluding dividends). Past performance does not predict future results.
Are Helus Pharma and Neurogene in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.